Pace links up with V-Tech to offer cardiac test panel
This article was originally published in Clinica
Executive Summary
Pace, a Canadian developer of diagnostic tests, has signed an exclusive OEM deal with V-Tech of El Monte, California, for the manufacture of rapid, quantitative tests to detect cardiac markers, including Pace's glycogen phosphorylase BB marker (GPBB). Under the agreement, Pace will pay $400,000 to develop GPBB tests jointly with V-Tech. In return, Pace will receive exclusive rights to the use of V-Tech's technology in testing for GPBB and non-exclusive rights to market and sell CK-MB and myoglobin tests, using similar technology.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.